<html>
<head>PUBMED IDs for GRIM19</head>
<body bgcolor='#C5F0F2'><h1>GRIM19</h1><a href='https://pubmed.ncbi.nlm.nih.gov/12163600/'>Viral interferon regulatory factor 1 of Kaposi's sarcoma-associated herpesvirus interacts with a cell death regulator, GRIM19, and inhibits interferon/retinoic acid-induced cell death.</a> August 7  2002<br><a href='https://pubmed.ncbi.nlm.nih.gov/15059901/'>GW112, a novel antiapoptotic protein that promotes tumor growth.</a> April 3  2004<br><a href='https://pubmed.ncbi.nlm.nih.gov/16428770/'>Identification of proteins differentially expressed in human monocytes exposed to Porphyromonas gingivalis and its purified components by high-throughput immunoblotting.</a> January 24  2006<br><a href='https://pubmed.ncbi.nlm.nih.gov/16969126/'>Identification and characterization of proteins interacting with Traf4, an enigmatic p53 target.</a> September 14  2006<br><a href='https://pubmed.ncbi.nlm.nih.gov/17049929/'>BCS1L is expressed in critical regions for neural development during ontogenesis in mice.</a> October 20  2006<br><a href='https://pubmed.ncbi.nlm.nih.gov/18278448/'>Construction of recombinant adenovirus carrying GRIM19 and its effect on SW480 cells.</a> February 19  2008<br><a href='https://pubmed.ncbi.nlm.nih.gov/20682646/'>Overexpression of GRIM-19 in cancer cells suppresses STAT3-mediated signal transduction and cancer growth.</a> December 14  2010<br><a href='https://pubmed.ncbi.nlm.nih.gov/20706288/'>Enhanced tumor suppression in vitro and in vivo by co-expression of survivin-specific siRNA and wild-type p53 protein.</a> March 11  2010<br><a href='https://pubmed.ncbi.nlm.nih.gov/24899100/'>Plasmid-based Stat3-specific siRNA and GRIM-19 inhibit the growth of thyroid cancer cells in vitro and in vivo.</a> February 13  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/24899082/'>Polymorphisms in cyclooxygenase-2 gene and risk of developing coal workers' pneumoconiosis: a case-control study.</a> April 22  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/25242535/'>Synergistic effects of co-expression plasmidâ€‘based ADAM10-specific siRNA and GRIM-19 on hepatocellular carcinoma in vitro and in vivo.</a> June 27  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/25901006/'>Mutation in NDUFA13/GRIM19 leads to early onset hypotonia, dyskinesia and sensorial deficiencies, and mitochondrial complex I instability.</a> April 29  2015<br><a href='https://pubmed.ncbi.nlm.nih.gov/27391226/'>GRIM19 ameliorates acute graft-versus-host disease (GVHD) by modulating Th17 and Treg cell balance through down-regulation of STAT3 and NF-AT activation.</a> July 9  2016<br></body></html>
